BEAT THE STREET GAME:
The American Society of Clinical Oncology, for the first time, is making research abstracts freely available to everyone ahead of the cancer drug confab. Here's a cheat sheet.
Acquisition Charges Hit Celgene
But the biotech beats Wall Street estimates on an adjusted basis, when factoring out expenses related to Pharmion.
05/08/08 - 10:18 AM EDT
FDA Panel Against Expansion of Cephalon's Fentora
The panel votes 17-3 against wider use of the pain drug.
05/06/08 - 05:36 PM EDT
Onyx's Strong Quarter Bolsters New CEO
Tony Coles' tenure got off to the right start with strong earnings and meaningful financial guidance.
05/07/08 - 07:28 AM EDT
Onyx Pharma Swings to Outsized Profit
The biotech company trounces Wall Street expectations for the first quarter on sales gains of Nexavar.
05/06/08 - 05:09 PM EDT
Discovery Labs Holds Out Hope for Surfaxin
The stock Monday regains some of its sharp Friday losses on the company's positive response to FDA delays. But is the reaction overly optimistic?
05/05/08 - 11:53 AM EDT
Feuerstein's Biotech-Stock Mailbag
Outlooks for SuperGen's Dacogen and Myriad Genetics' Flurizan; more Q&A on ImClone's Erbitux, and more.
05/03/08 - 11:10 AM EDT
Biotech Notebook: Progenics, Wyeth
Projecting potential market share for newly approved Relistor; monitoring exec moves at Introgen; and more.
04/30/08 - 09:26 AM EDT
Discovery Labs Awaits FDA Word on Surfaxin
A regulatory decision on the lung treatment could come May 1, but even with approval the biotech will have to work for every bit of upside.
04/29/08 - 02:02 PM EDT
Biogen, Genentech's Rituxan Fails New Study
The drug failed to benefit patients with lupus, according to new late-stage study data.
04/29/08 - 10:12 AM EDT
Vertex Hep C Drug Still Leads Schering
Data presented this weekend show telaprevir is the leader.
04/28/08 - 08:47 AM EDT
Feuerstein's Biotech-Stock Mailbag
What to expect when ImClone presents the latest Erbitux data at ASCO in June.
04/26/08 - 09:57 AM EDT
symbol throughout our site to look up items.
